Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation

Journal Article · Thu Feb 01 04:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2006.09.010· OSTI ID:20944671

Orio, Peter ^[1]; Wallner, Kent ^[2]; Merrick, Gregory ^[3]; Herstein, Andrew ^[4]; Mitsuyama, Paul ^[1]; Thornton, Ken ^[5]; Butler, Wayne ^[3]; Sutlief, Steven ^[1]

---

1. Department of Radiation Oncology, University of Washington, Seattle, WA (United States)
2. Department of Radiation Oncology, University of Washington, Seattle, WA (United States) and Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA (United States) and Group Health Cooperative, Seattle, WA (United States)
3. Schiffler Cancer Center, Wheeling, WV (United States)
4. Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA (United States)
5. Varian Medical Systems, Charlottesville, VA (United States)

Purpose: To analyze the role of dosimetric quality parameters in maximizing cancer eradication in higher risk prostate cancer patients treated with palladium (Pd)-103 and supplemental beam radiation. Methods: One-hundred-seventy-nine patients treated with Pd-103 and supplemental beam radiation, with minimum 2 years follow-up prostate-specific antigen (PSA) values and posttreatment computed tomography scans were analyzed. Dosimetric parameters included the V100 (percent of the postimplant volume covered by the prescription dose), the D90 (the minimum dose that covered 90% of the post implant volume), and the treatment margins (the radial distance between the prostatic edge and the prescription isodose). Treatment margins (TMs) were calculated using premarket software. Results: Freedom from biochemical failure was 79% at 3 years, with 92 of the 179 patients (51%) followed beyond 3 years. In comparing patients who did or did not achieve biochemical control, the most striking differences were in biologic factors of pretreatment PSA and Gleason score. The V100, D90, and average TM all showed nonsignificant trends to higher values in patients with biochemical control. In multivariate analysis of each of the three dosimetric parameters against PSA and Gleason score, TM showed the strongest correlation with biochemical control (p = 0.19). Conclusions: For patients with intermediate and high-risk prostate cancer treated with Pd-103 brachytherapy and external beam radiation, biologic factors (PSA and Gleason score) were the most important determinants of cancer eradication. However, there is a trend to better outcomes among patients with higher quality implant parameters, suggesting that attention to implant quality will maximize the likelihood of cure.

• OSTI ID: 20944671
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 2 Vol. 67; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIGENS
BRACHYTHERAPY
CARCINOMAS
COMPUTER CODES
COMPUTERIZED TOMOGRAPHY
DOSIMETRY
MULTIVARIATE ANALYSIS
PALLADIUM 103
PATIENTS
PROSTATE
RADIATION DOSES
RADIATION SOURCE IMPLANTS